Dr. Lal Path Labs Ltd
Nippon India Mutual Fund trimmed its stake in Dr. Lal Path Labs Ltd from 2.63% to 2.19%, selling 7,47,374 shares.
A leading diagnostic services provider in India, Dr. Lal PathLabs operates an integrated nationwide network delivering laboratory tests and comprehensive healthcare services. The company serves individual patients, hospitals, healthcare providers, and corporate clients through core diagnostic testing, disease diagnosis, prevention, monitoring, and treatment support. Its distinctive strength lies in combining consumer accessibility with a broad range of diagnostic capabilities and related health services across the country.
India's fifth-largest AMC with over Rs 6 lakh crore in AUM, backed by Japan's Nippon Life Insurance which holds majority stake. Formerly Reliance MF, rebranded in 2019 after Nippon's acquisition. Sailesh Raj Bhan has run the equity book for over two decades and is one of India's most experienced active managers. Known for sector rotational calls and a deep research bench.